Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $283.96 (market cap $39.89B), while ProShares UltraPro Short QQQ ETF trades at $38.98. Which is the better fit depends on your goals.
| ALNY | SQQQ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $97.60 |
52-Week Low | $278.09 | $36.31 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SQQQ trades at $37.78, down 0.84% on the day, with a bearish technical signal driven by moving averages. The ETF, designed to deliver -3x the daily return of the Nasdaq-100, faces structural decay from daily resets, evidenced by long-term value erosion. Recent news highlights its role as a tactical hedge rather than a long-term holding, with short interest rising 19.4% in March 2026 (Defense World, 2026-04-19).
Outlook remains highly speculative; SQQQ offers potential for short-term gains during Nasdaq declines but carries extreme risk from volatility decay. Investors must actively manage positions due to the ETF's unsuitability for buy-and-hold strategies, with success dependent on precise market timing amid bearish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
